Overview
Portfolio
More
120 Capital
Brentwood, United States
120 Capital is a venture fund focused on life‑science and healthcare companies developing breakthrough therapeutics, platforms, and medical technologies. The firm backs innovative biotech, digital health, and med‑device...
Portfolio
14+
Employees
50+
Founded
2000
AUM
≈ $2.0B
Investment focus
Stages
Series A → Series C+
Industries
BiotechnologyDigital HealthHealthcare TechnologyMedical Devices
Geographic scope
Global
Sources
120 Capital
120 Capital is a venture fund focused on life‑science and healthcare companies developing breakthrough therapeutics, platforms, and medical technologies. The firm backs innovative biotech, digital health, and med‑device ventures that address unmet medical needs and have the potential for global impact. It leverages deep industry expertise and networks to help portfolio companies advance from early clinical stages to commercialization.
Portfolio
14+
Employees
50+
Founded
2000
AUM
≈ $2.0B
Stages
Series A → Series C+
Industries
BiotechnologyDigital HealthHealthcare TechnologyMedical Devices
Geographic scope
Global
Sources
Showing 13 of 13 matched portfolio companies
Celestial develops mRNA vaccines and therapeutics for infectious diseases and cancer. Their technology aims to provide novel preventative and treatment options through advanced mRNA delivery.
5+
300+Approximate amount of employees
Funding: $725.0K
Rough estimate of the amount of funding raised
Funding: $725.0K
Rough estimate of the amount of funding raised
Curbon provides AI‑powered bot detection and mitigation for web forms, helping sites identify and block automated submissions. Its solution adds invisible verification layers that assess visitor behavior and risk, reducing spam and abuse without disrupting genuine users.
Dewpoint Therapeutics is developing a drug platform that targets biomolecular condensates, which are implicated in the dysregulation of complex diseases. By integrating AI with advanced experimental technologies, the company aims to create therapies for conditions previously considered undruggable.
Funding: $286.2M
Rough estimate of the amount of funding raised
Funding: $286.2M
Rough estimate of the amount of funding raised
Exo Therapeutics utilizes its ExoSight™ platform to identify and develop small molecule inhibitors targeting exosites on enzymes involved in oncology and inflammation. This approach aims to enhance the modulation of enzyme activity, addressing the challenge of drugging previously inaccessible targets.
Funding: $102.8M
Rough estimate of the amount of funding raised
Funding: $102.8M
Rough estimate of the amount of funding raised
Develops RIPTAC™ therapeutics, a novel class of precision cancer treatments that use a protein-protein interaction mechanism to selectively bind tumor-specific proteins and essential cellular functions, leading to targeted cancer cell death. This approach addresses the limitations of traditional therapies by offering a more precise and effective method for treating major solid tumors.
30+
5K+Approximate amount of employees
Funding: $227.1M
Rough estimate of the amount of funding raised
Funding: $227.1M
Rough estimate of the amount of funding raised
HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.
Immunitas Therapeutics utilizes single-cell genomics to develop targeted antibody-based therapies for cancer and autoimmune diseases, focusing on the CD161-CLEC2D pathway. Their lead candidate, IMT-009, is currently in clinical trials for treating refractory tumors, addressing the need for effective treatments in patients with limited options.
Funding: $97.0M
Rough estimate of the amount of funding raised
Agent Capital
Agent Capital
Funding: $97.0M
Rough estimate of the amount of funding raised
Insignis Therapeutics is developing IN-001, a sublingual epinephrine spray designed to provide a needle-free, stable treatment for anaphylaxis that remains effective across a wide temperature range. This product addresses the limitations of traditional epinephrine auto-injectors, enabling individuals with severe allergies to manage their condition more conveniently and confidently.
Founded 2018
Develops targeted therapies for complement-mediated diseases using a proprietary LOGIC platform that integrates lead identification, optimization, in-vivo confirmation, and validation tools. By focusing on validated targets within the complement cascade, the company addresses the challenges of developing effective treatments for complex autoimmune and inflammatory conditions, with nine investigational assets in its pipeline.
MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.
Funding: $13.0M
Rough estimate of the amount of funding raised
Funding: $13.0M
Rough estimate of the amount of funding raised
Senti Biosciences develops proprietary Gene Circuits using synthetic biology to reprogram cells for targeted cancer therapies, enabling precise elimination of cancer cells while sparing healthy tissue. Their lead product candidate, SENTI-202, is designed for the treatment of acute myeloid leukemia, addressing the need for more effective and specific cancer treatments.
Funding: $47.6M
Rough estimate of the amount of funding raised
Celadon Partners
Celadon Partners
Funding: $47.6M
Rough estimate of the amount of funding raised
V-Flow Medical develops medical devices that utilize advanced catheter-based technologies to treat venous vascular diseases, such as chronic venous insufficiency and deep vein thrombosis. Their solutions aim to improve patient outcomes by enhancing blood flow and reducing complications associated with these conditions.
5+
100+Approximate amount of employees
Funding: $80.0M
Rough estimate of the amount of funding raised
Funding: $80.0M
Rough estimate of the amount of funding raised
The startup develops radiopharmaceuticals that utilize radionuclide labeling for targeted tumor diagnosis and treatment. Their products provide precise therapeutic options for patients with cancer, enhancing treatment efficacy while minimizing side effects.
Showing 1 of 1 unmatched portfolio company